Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses (Q44592639)

From Wikidata
Jump to navigation Jump to search
scientific article published on October 1, 2003
edit
Language Label Description Also known as
English
Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses
scientific article published on October 1, 2003

    Statements

    Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses (English)
    2702-3; author reply 2703-4

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit